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Three adult (≥18 years) cohorts from The Epidemiology and
Natural History of Asthma: Outcomes and Treatment Regimens
(TENOR) 3-year observational study were deﬁned: patients on
SFC Low-Dose (100/50 or 250/50 μg), patients on SFC High-
Dose (500/50 μg), and patients on other medications (including
salmeterol and ﬂuticasone), but not on SFC. Using standard
regression methods, we computed unadjusted and propensity
score adjusted differences in 24 month outcomes between the
treatment cohorts. RESULTS: After adjustment for confounding,
the Low-Dose SFC cohort had higher asthma-related quality of
life (P = 0.0026), fewer asthma control problems (P = 0.0001),
similar rates of exacerbations (P = 0.8932), marginally higher
FEV1 (P = 0.0777) and lower odds of having severe asthma (P
= 0.0454) compared with controls (patients never on SFC). After
adjustment for confounding, the High-Dose SFC cohort had no
difference in asthma-related quality of life, asthma control prob-
lems, or exacerbation rates (P = 0.1879, 0.3015, 0.3560 respec-
tively), higher FEV1 (P = 0.0011), and higher odds of having
severe asthma (P = 0.0137). CONCLUSIONS: The results
support evidence that some asthmatics achieve better control
while taking low-dose SFC, but also suggest that high-dose SFC
fails to provide clinically signiﬁcant beneﬁt in terms of most
asthma-related health outcomes when compared to similar
patients not taking high-dose SFC. These ﬁndings may highlight
an unmet need in severe or difﬁcult-to-treat asthma and call for
alternative therapeutic approaches in those unable to attain
asthma control with or without SFC.
PAA2
EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER
THERAPY FOR MILD-PERSISTENT ASTHMA
Takemoto SK, Swindle J
Saint Louis University, Saint Louis, MO, USA
OBJECTIVES: Asthma exacerbation rates in a large Midwest
health plan were compared for single and dual controllers.
METHODS: The asthma cohort included 788 patients pre-
scribed at least 1 SABA and 2 controller prescriptions during a
6 month intake period, with mild persistent severity deﬁned by
rates of ED or hospital admission, SABA and OCS ﬁlls. Patients
older than age 55, diagnosed with COPD or prescribed more
than one type of controller were excluded. Exacerbations were
deﬁned by Kaplan-Meier, as time to asthma-related hospital or
ED admission. Signiﬁcance was further tested using Cox pro-
portional hazards stratiﬁed by age, gender, control, severity, and
adherence during a six-month pre-index period. RESULTS:
Leukotriene modiﬁers (LM) were prescribed as a single con-
troller for 38% of patients, inhaled corticosteroid (ICS) for 27%,
and dual controller (DC, ﬂuticasone/salmeterol) for 36%. DC
were prescribed most often in older adults (55%), while LM
were most often prescribed in children (62%). Asthma severity
as deﬁned by the number of SABA and OCS ﬁlls and exacerba-
tions in the intake period was similar for the three cohorts.
Asthma control (>4x controller/SABA) was highest for LM
(89%). Controller adherence rates were lowest in the ICS cohort
with 76% ﬁlling <4 prescriptions compared to 53% for DC and
44% for LM. Two-year exacerbation rates were 19% for ICS,
20% for LM and 18% for DC (P = 0.99). In the multivariate
model, older adults less likely suffered exacerbations compared
to children (hazard ratio = 0.63, 95% CI 0.44–0.91, P = 0.013).
CONCLUSION: An algorithm was developed to identify
patients with mild-persistent asthma in administrative claims.
Multivariate models were constructed to control for demo-
graphics, asthma severity, control and adherence rates. Kaplan-
Meier statistics indicates exacerbation rates were highest among
children, but were similar in patients receiving LM, ICS or DC.
PAA3
EVALUATION OF RISK FACTORS AND PREDICTORS OF
HEALTH OUTCOMES AMONG PERSONS WITH ASTHMA
Smith KL1,Warholak-Jackson T2, Malone DC2,Armstrong EP2,
Rehfeld RA2
1University of Arizona College of Pharmacy,Tucson, AZ, USA,
2University of Arizona,Tucson, AZ, USA
OBJECTIVES: To examine risk factors associated with health
care utilization in Arizona Medicaid patients with asthma.
METHODS: Data were obtained from Arizona Medicaid
between 1/1/2002 and 12/31/2003. Inclusion criteria consisted
of persons with an asthma diagnosis (ICD9-CM 493.xx), 5–62
years of age; and were new users of inhaled-corticosteroids (ICS),
combination ICS+long-acting beta-agonist, or leukotriene-
modiﬁers. Factors examined included age, geographic location
(urban/rural), race/ethnicity (White, non-Hispanic Black, His-
panic, other), medication adherence, pre-period short-acting
beta-agonist use (SABA), and co-morbidities. Utilization mea-
sures examined included post-period SABA use, exacerbations
measured by emergency-room or hospital visits, asthma-related
and total health care costs. Analyses for utilization measures
were performed using negative binomial, logistic regression, and
generalized linear modeling gamma-family, log-link, respectively.
RESULTS: A total of 3013 subjects met inclusion/exclusion cri-
teria and had a mean age (+SD) of 24.7 + 13.7 years. Urban res-
idents were 54% more likely to have an exacerbation than rural
residents (odds ratio-OR 0.46, 95%CI: 0.30–0.79). Age (years
18–39) was a signiﬁcant predictor across all analyses: SABA use
(incidence rate ratio-IRR 1.24, 95%CI: 1.06–1.44); exacer-
bations (OR 2.22, 95%CI: 1.34–3.68); mean asthma cost
($702.47, 95%CI: $600.07–822.34); mean total health care cost
($5445.67, 95%CI: $4852.18–6111.76). Age (years 40–62) sig-
niﬁcantly predicted mean total health care cost: $5662.88,
95%CI: $4814.67–6660.53. Males were 47% less likely to have
an exacerbation than females (OR 0.53, 95%CI: 0.30–0.91).
Exacerbations were not different between race/ethnicity cate-
gories. Predicted mean asthma-related costs were not different
between Whites ($590.65, 95%CI: 508.80–565.68), Blacks
(637.68, 95%CI: 499.10–814.75), or Hispanics (534.79,
95%CI: 466.14–613.55). CONCLUSION: Results of these
analyses found urban areas had higher rates of asthma-related
hospital visits compared to rural counties, but no signiﬁcant dif-
ference in asthma-costs between urban and rural areas. Persons
with asthma aged 18–39 had higher rates of asthma-related
emergency-room visits/hospitalizations and costs than those aged
5–17 and 40–62. Race/ethnicity was not a signiﬁcant predictor
of outcomes or asthma-related costs.
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OBJECTIVES: To review the health economic literature for
drugs that have since been withdrawn for safety reasons. To
assess the cost-effectiveness of the non-sedating anti-histamine,
terfenadine (withdrawn in 1998 for its cardiotoxicity) compared
with chlorpheniramine, a sedating anti-histamine which is still
available. METHODS: Literature searches of economic evalua-
tions of drug that have been withdrawn since 1980 were 
conducted. A decision analysis comparing terfenadine with
chlorpheniramine was developed. Observational data were
obtained for estimates of the incidence of ventricular dysryth-
mias, the incidence of serious injuries as a consequence of seda-
tion with chlorpheniramine, and the risk of death resulting from
arrhythmias or serious injuries. Health state utilities and data on
